HDAC9 and cancer: Thus, it is suggested that a single molecule that simultaneously inhibits HDAC and RTK activities targeting multiple biological molecules and multiple signal pathways can not only enhance drug efficacy but also can have additive or even synergistic antitumor effects and can overcome the problems of cancer resistance and relapse.